Xencor, Inc.
NASDAQ:XNCR · NASDAQ Global Market
-$0.13 today
Vol 1.52M · Avg 0.80M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:XNCR · Revenue to Net Income
Key Ratios
Analysis
$97.4M of revenue converted into -$172.4M of net income for the selected period. Gross margin is 17.3% and net margin is -744.4%, showing how much revenue survives after costs and taxes. EPS is $-2.29, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $125.6M +13.7% | $110.5M -36.7% | $174.6M +6.1% | $164.6M -40.2% | $275.1M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $10.5M -95.4% | $227.7M | $0 -100.0% | $199.6M +3.7% | $192.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $115.1M +198.2% | -$117.2M -167.1% | $174.6M +599.1% | -$35.0M -142.4% | $82.6M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 91.6% +197.7pp | -106.1% -206.1pp | 100.0% +121.3pp | -21.3% -51.3pp | 30.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $239.4M +5.2% | $227.7M -10.2% | $253.6M +27.1% | $199.6M +3.7% | $192.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $63.6M +8.1% | $58.9M +10.3% | $53.4M +12.4% | $47.5M +22.3% | $38.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $292.6M +377.9% | $61.2M -80.1% | $307.0M +546.4% | $47.5M +22.3% | $38.8M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $10.5M -13.2% | $12.1M +5.3% | $11.5M +30.7% | $8.8M +17.5% | $7.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$47.0M +74.8% | -$186.2M -82.6% | -$102.0M -123.1% | -$45.7M -150.7% | $90.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -37.4% +131.1pp | -168.5% -110.1pp | -58.4% -30.6pp | -27.8% -60.5pp | 32.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$177.5M +0.5% | -$178.4M -34.8% | -$132.4M -60.5% | -$82.5M -288.4% | $43.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -141.4% +20.1pp | -161.5% -85.7pp | -75.8% -25.7pp | -50.1% -66.0pp | 15.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $27.5M -13.8% | $31.9M +71.4% | $18.6M +286.7% | $4.8M +458.8% | $862.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $31.9M -12.9% | $36.6M | $0 | $0 -100.0% | $13.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $87.9M +255.5% | -$56.5M -544.0% | $12.7M -54.5% | $28.0M -28.0% | $38.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$89.4M +61.9% | -$234.9M -96.4% | -$119.6M -119.5% | -$54.5M -166.0% | $82.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -71.2% +141.4pp | -212.6% -144.1pp | -68.5% -35.4pp | -33.1% -63.2pp | 30.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $2.5M +54.9% | $1.6M -88.2% | $13.7M +1930.0% | $673.0K | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$91.9M +60.5% | -$232.6M -74.7% | -$133.1M -141.3% | -$55.2M -166.8% | $82.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | -73.2% +137.3pp | -210.5% -134.3pp | -76.2% -42.7pp | -33.5% -63.6pp | 30.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +65.4% | -$4 -72.1% | -$2 -123.7% | -$1 -165.5% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +65.4% | -$4 -72.1% | -$2 -123.7% | -$1 -167.9% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $74.2M +14.1% | $65.0M +7.5% | $60.5M +1.4% | $59.7M +2.2% | $58.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $74.2M +14.1% | $65.0M +7.5% | $60.5M +1.4% | $59.7M -1.4% | $60.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.55B
AnaptysBio, Inc.
NASDAQ:ANAB
$2.39B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.87B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.58B
Mind Medicine (MindMed) Inc.
MNMD
$1.56B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.49B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$855.38M
Oculis Holding AG
NASDAQ:OCS
$628.86M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$606.41M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does XNCR generate?
Xencor, Inc. (XNCR) reported $125.58M of revenue in fiscal 2025.
Is XNCR profitable?
Xencor, Inc. (XNCR) reported -$91,923,000.00 of net income, with a net margin of -73.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.